tradingkey.logo

Check Cap Ltd

CHEK
1.610USD
0.0000.00%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
9.42MCap. mercado
PérdidaP/E TTM

Más Datos de Check Cap Ltd Compañía

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

Información de Check Cap Ltd

Símbolo de cotizaciónCHEK
Nombre de la empresaCheck Cap Ltd
Fecha de salida a bolsaFeb 19, 2015
Director ejecutivoOvadia (Alex)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 19
Dirección29 Abba Hushi Ave.
Ciudad
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal3009000
Teléfono97248303401
Sitio Webhttps://check-cap.com/
Símbolo de cotizaciónCHEK
Fecha de salida a bolsaFeb 19, 2015
Director ejecutivoOvadia (Alex)

Ejecutivos de Check Cap Ltd

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
--
--
Dr. Mary Jo Gorman, M.D.
Dr. Mary Jo Gorman, M.D.
Independent Director
Independent Director
--
--
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
--
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
--
--
Mr. Joshua (Shuki) Belkar
Mr. Joshua (Shuki) Belkar
Vice President - Operations
Vice President - Operations
--
--
Mr. Israel Hershko
Mr. Israel Hershko
Vice President - Quality Assurance and Regulatory Affairs
Vice President - Quality Assurance and Regulatory Affairs
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
--
--
Dr. Mary Jo Gorman, M.D.
Dr. Mary Jo Gorman, M.D.
Independent Director
Independent Director
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
EquityLine Alternate Assets GP Inc
10.46%
Ramanathan (Vijay)
4.94%
Symetryx Corp
4.65%
BNP Paribas Securities Corp. North America
0.30%
Dimensional Fund Advisors, L.P.
0.12%
Otro
79.53%
Accionistas
Accionistas
Proporción
EquityLine Alternate Assets GP Inc
10.46%
Ramanathan (Vijay)
4.94%
Symetryx Corp
4.65%
BNP Paribas Securities Corp. North America
0.30%
Dimensional Fund Advisors, L.P.
0.12%
Otro
79.53%
Tipos de accionistas
Accionistas
Proporción
Corporation
15.11%
Individual Investor
4.94%
Research Firm
0.41%
Investment Advisor/Hedge Fund
0.16%
Investment Advisor
0.11%
Bank and Trust
0.05%
Otro
79.22%

Participación institucional

Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
31
46.22K
2.97%
--
2025Q3
31
46.22K
2.97%
-83.61K
2025Q2
30
129.91K
3.13%
+25.59K
2025Q1
31
104.32K
4.46%
-156.41K
2024Q4
32
147.67K
2.55%
+134.65K
2024Q3
33
13.02K
3.40%
+4.10K
2024Q2
36
9.37K
3.50%
-1.09K
2024Q1
41
13.66K
3.76%
-206.06K
2023Q4
43
68.48K
6.43%
+25.25K
2023Q3
45
28.34K
6.39%
+11.71K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
EquityLine Alternate Assets GP Inc
762.72K
10.46%
--
--
Dec 31, 2024
Ramanathan (Vijay)
360.00K
4.94%
--
--
Dec 31, 2024
Symetryx Corp
338.63K
4.65%
--
--
Dec 31, 2024
BNP Paribas Securities Corp. North America
21.64K
0.3%
+1.50K
+7.45%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
8.96K
0.12%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
476.00
0.01%
-5.47K
-91.99%
Sep 30, 2025
Morgan Stanley & Co. LLC
6.30K
0.09%
+2.30K
+57.44%
Sep 30, 2025
National Bank of Canada
3.27K
0.04%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
2.93K
0.04%
--
--
Nov 30, 2025
J.P. Morgan Securities LLC
1.50K
0.02%
-210.00
-12.28%
Sep 30, 2025
Ver más

ETFs relacionados

Nombre
Proporción
Sin datos

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
KeyAI